MOTS-c Benefits: What the Research Shows
Last reviewed
MOTS-c is marketed for metabolism, weight loss and exercise performance. Here's where those claims come from, and how much of the research was done in people.
The short version
- The headline results come from a 2015 study in mice.
- The only human trial we found tested a related experimental drug, not MOTS-c itself, in about 20 people for 4 weeks.
- MOTS-c isn't FDA-approved.
Evidence at a glance
| Type of study | What exists |
|---|---|
| Animal | The 2015 discovery study in mice, plus later animal research. |
| MOTS-c in people | None found We found no published trials of MOTS-c itself in people. |
| Related drug in people | One small trial CB4211, a MOTS-c-derived drug, tested for 4 weeks in 2021. |
What MOTS-c is
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, the small set of genes inside the cell's energy-producing mitochondria. Researchers first described it in 2015.
The mouse research
In the 2015 discovery study, published in Cell Metabolism, MOTS-c mainly acted on skeletal muscle. Treating mice with it prevented insulin resistance caused by aging and by a high-fat diet, and prevented diet-induced obesity. That's where most of today's metabolism and weight-loss marketing comes from.
The one human trial: a related drug
CB4211, an experimental drug derived from MOTS-c, was tested in 2021 in adults with obesity and fatty liver disease. In the placebo-controlled part of the study, 23 people were randomized and 20 completed the 4 weeks of daily injections. The company reported:
- It was well tolerated with no serious side effects, but injection-site reactions were common: 79% of people on the drug versus 33% on placebo.
- Liver enzymes (ALT and AST) and blood sugar fell more than with placebo, as exploratory findings.
- Body weight showed only a trend downward, not a statistically significant change.
That's one short, small study of a different molecule, reported by the company that developed it.
FDA status
MOTS-c isn't FDA-approved. The FDA removed it from its compounding "significant safety concerns" list in April 2026, and an advisory committee recommended it for the list of ingredients compounding pharmacies can use in July 2026, against FDA staff's recommendation. The FDA hasn't acted on that. Latest status: FDA status tracker. For weight loss specifically, see which peptides are FDA-approved.
Frequently asked questions
What are the benefits of MOTS-c?
In mice, it prevented diet-induced obesity and insulin resistance. That hasn't been shown in people.
Does MOTS-c help with weight loss?
There's no direct human evidence. A 4-week trial of a related drug showed only a non-significant trend toward lower weight.
Is MOTS-c FDA approved?
No. It's awaiting an FDA decision on compounding after a July 2026 advisory vote.
How do people mix MOTS-c?
It's sold as a powder that's reconstituted with water. Our MOTS-c reconstitution calculator does the arithmetic; it doesn't recommend an amount.
Sources
- Lee et al., The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis, Cell Metabolism (2015)
- CohBar investor presentation on CB4211 phase 1a/1b results, filed with the SEC (August 2021)
- Patient Worthy: New data available on CB4211 for NASH and obesity (2021)
- Goodwin: FDA's 2026 peptide compounding changes
- Frier Levitt: FDA advisory committee peptide vote (2026)